Welcome to our dedicated page for Outset Medical news (Ticker: OM), a resource for investors and traders seeking the latest updates and insights on Outset Medical stock.
Outset Medical, Inc. (symbol: OM) is a pioneering medical technology company committed to revolutionizing the dialysis experience. The company’s primary product, Tablo, is an innovative dialysis machine designed to simplify and streamline the process of Renal Replacement Therapy. By focusing on a patient-centric approach, Outset Medical places patient care, ease of use, and cost-efficiency at the forefront of its operations.
The Tablo dialysis system is built with a user-friendly touchscreen display that offers step-by-step visual and conversational instructions, making it accessible to both patients and caregivers, regardless of their experience level. This intuitive design dramatically reduces the complexity and cost associated with traditional dialysis treatments. Tablo can be used across various settings, including hospitals, chronic care dialysis clinics, and at home, making it a versatile solution for renal care.
Outset Medical’s mission is to improve the care experience for patients, families, providers, and physicians, while also enhancing cost-efficiencies for healthcare providers. The company achieves this by combining expertise from different healthcare fields, fostering an environment of cross-disciplinary innovation. This approach has led to significant advancements in dialysis technology and patient care.
Recent achievements include regulatory approvals and partnerships aimed at expanding Tablo’s reach and improving its functionalities. Financially, Outset Medical has shown robust growth, supported by a dedicated team of professionals and continuous innovation in their product offerings. The company's efforts are geared towards giving people their time back by reducing the dialysis process's complexity and duration.
Stay updated with the latest developments and news about Outset Medical, Inc. to learn how this industry leader is transforming renal care.
Outset Medical, Inc. (NASDAQ: OM), a pioneering medical technology firm, announced its participation in two upcoming investor conferences. The Bank of America Securities 2023 Health Care Conference is scheduled for May 9, 2023, at 1:40 PM PT, while the RBC Capital Markets Global Healthcare Conference will take place on May 17, 2023, at 5:00 AM PT. Live and archived webcasts of these events will be accessible via the Outset Investors' website.
Outset's flagship product, the Tablo Hemodialysis System, aims to streamline dialysis, making it more accessible and efficient for patients and providers. This innovative system integrates water purification and on-demand dialysate production, positioning it as a versatile solution for dialysis care.
Outset Medical, Inc. (NASDAQ: OM) has released five new abstracts at the National Kidney Foundation Spring Clinical Meetings highlighting innovations in home hemodialysis (HHD) and gender biases in nephrology. The studies demonstrate clinical and financial benefits of HHD, particularly in Hawaii, where Tablo was implemented effectively under challenging conditions. Key findings include a potential savings of
Outset Medical, Inc. (NASDAQ: OM) announced plans to release its financial results for Q1 2023 on May 3, 2023, after market close. CEO Leslie Trigg and CFO Nabeel Ahmed will host a conference call at 2:00 PM PT (5:00 PM ET) on the same day to discuss the results. The company focuses on revolutionizing dialysis with its Tablo® Hemodialysis System, which simplifies operational processes and enhances patient care. The system integrates water purification and dialysate production, serving as a mobile dialysis clinic. Interested parties can register online for the call and access a live or archived webcast on the Outset Investors page.
Outset Medical, Inc. (Nasdaq: OM), a leader in medical technology, announces participation in a fireside chat at the 43rd Annual Cowen Health Care Conference on Wednesday, March 8, 2023, at 9:50 a.m. PT / 12:50 p.m. ET. The event will be available via live and archived webcast on the Outset website.
Outset is known for its innovative Tablo Hemodialysis System, which simplifies dialysis by allowing for its use in various settings, from hospitals to homes. This FDA-cleared technology enhances patient care and operational efficiency, integrating water purification and on-demand dialysate production.
Outset Medical, Inc. (NASDAQ: OM) reported its financial results for Q4 and full year 2022. Q4 revenue was $32.0 million, up 14.0% year-over-year, and full-year revenue reached $115.4 million, marking a 12.4% increase. Gross margin for Q4 was 16.5%, improving significantly from 11.8% in Q4 2021, while full-year gross margin stood at 15.5%. The company increased its Tablo systems installation base by 54% year-over-year. Operating expenses rose to $45.1 million, with a net loss of $41.4 million for Q4. For 2023, Outset maintains revenue guidance of $140 to $150 million, projecting growth of approximately 22% to 30% over 2022.
Outset Medical, Inc. (NASDAQ: OM) will release its financial results for Q4 and full year 2022 on February 13, 2023, post-market. A conference call hosted by CEO Leslie Trigg and CFO Nabeel Ahmed will take place at 2:00 p.m. PT (5:00 p.m. ET) on the same day to discuss the outcomes. Outset's innovative Tablo® Hemodialysis System aims to transform dialysis by simplifying operations and making care accessible in various settings. The system integrates water purification and on-demand dialysate production, enhancing the dialysis experience for patients.
Outset Medical, Inc. (NASDAQ: OM) announced its expected fourth quarter and fiscal year 2022 revenues, projecting approximately
Outset Medical, Inc. (Nasdaq: OM) announces its participation in the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 11:15 am PT / 2:15 pm ET. The company focuses on innovative dialysis technology, specifically the Tablo Hemodialysis System, designed to reduce costs and complexity in dialysis treatments. The Tablo system, FDA cleared for both hospital and home use, allows healthcare providers to deliver dialysis care more efficiently. A live and archived webcast will be available on Outset's Investors webpage.
Outset Medical, Inc. (Nasdaq: OM) announces participation in a virtual panel at the BofA Securities Home Care Conference on December 6, 2022, at 12:10 PM PT. The discussion will feature CEO Leslie Trigg and CMO Michael Aragon, alongside two home dialysis patients, focusing on home hemodialysis and end-stage renal disease management. A live and archived webcast will be accessible on the Investors section of Outset’s website. Outset's Tablo® Hemodialysis System aims to simplify dialysis and enhance patient care.
FAQ
What is the current stock price of Outset Medical (OM)?
What is the market cap of Outset Medical (OM)?
What is Outset Medical, Inc.?
What product does Outset Medical offer?
How does the Tablo dialysis system work?
In what settings can Tablo be used?
What is the company's main mission?
Who can use the Tablo machine?
What is unique about the Tablo machine?
How does Outset Medical foster innovation?
What recent achievements does Outset Medical have?
How has Outset Medical performed financially?
